Journal of Clinical Endocrinology & Metabolism, Vol 65, 512-518, Copyright © 1987 by Endocrine Society

ARTICLES

High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL

A Golay, L Zech, MZ Shi, YA Chiou, GM Reaven and YD Chen

High density lipoprotein (HDL) kinetics were studied by injecting [3H]apoprotein A-I (apoA-I)/HDL into 12 subjects with normal glucose tolerance and 12 patients with noninsulin-dependent diabetes mellitus (NIDDM). The results indicate that the mean fractional catabolic rate (FCR) of apoA-I/HDL was significantly faster [0.63 +/- 0.07 (+/- SEM) vs. 0.39 +/- 0.02 1/day; P less than 0.001] and the apoA-I/HDL synthetic rate greater (29.4 +/- 2.9 vs. 22.9 +/- 1.3 mg/kg X day; P less than 0.02) in patients with NIDDM than in normal subjects. Furthermore, there were statistically significant inverse relationships between apoA-I/HDL FCR and plasma levels of both HDL cholesterol (r = - 0.71; P less than 0.001) and apoA-I (r = -0.63; P less than 0.001). In addition, the increase in apoA-I/HDL FCR was directly related to fasting plasma glucose (r = 0.78; P less than 0.001) and insulin (r = 0.76; P less than 0.001) concentrations. These data support the view that the decrease in plasma HDL cholesterol and apoA-I levels commonly found in patients with noninsulin-dependent diabetes is due to an increase in the catabolic rate of apoA-I/HDL secondary to the defects in carbohydrate metabolism present in these patients.

This article has been cited by other articles:

				B. W. McCrindle, E. M. Urbina, B. A. Dennison, M. S. Jacobson, J. Steinberger, A. P. Rocchini, L. L. Hayman, and S. R. Daniels Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing Circulation, April 10, 2007; 115(14): 1948 - 1967. [Abstract] [Full Text] [PDF]

				R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF]

				G. M Reaven The metabolic syndrome: is this diagnosis necessary? Am. J. Clinical Nutrition, June 1, 2006; 83(6): 1237 - 1247. [Abstract] [Full Text] [PDF]

				H. N. Ginsberg REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 383 - 392. [Abstract] [Full Text] [PDF]

				J. Steinberger and S. R. Daniels Obesity, Insulin Resistance, Diabetes, and Cardiovascular Risk in Children: An American Heart Association Scientific Statement From the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism) Circulation, March 18, 2003; 107(10): 1448 - 1453. [Full Text] [PDF]

				C. M. Hoehner, K. J. Greenlund, S. Rith-Najarian, M. L. Casper, and W. M. McClellan Association of the Insulin Resistance Syndrome and Microalbuminuria among Nondiabetic Native Americans.The Inter-Tribal Heart Project J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1626 - 1634. [Abstract] [Full Text] [PDF]

				J. McEneny, C. McMaster, E. R. Trimble, and I. S. Young Rapid isolation of VLDL subfractions: assessment of composition and susceptibility to copper-mediated oxidation J. Lipid Res., May 1, 2002; 43(5): 824 - 831. [Abstract] [Full Text] [PDF]

				R. Frénais, H. Nazih, K. Ouguerram, C. Maugeais, Y. Zaïr, J. M. Bard, B. Charbonnel, T. Magot, and M. Krempf In Vivo Evidence for the Role of Lipoprotein Lipase Activity in the Regulation of Apolipoprotein AI Metabolism: A Kinetic Study in Control Subjects and Patients with Type II Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1962 - 1967. [Abstract] [Full Text]